APP and Alzheimer disease: The strategy of targeting the APP 5′-UTR to reduce APP expression and Aβ amyloid formation has been validated by the usage of novel IRE chemical inhibitors to alleviate APP and amyloid levels as well as cognitive decline in the TgCRND8 AD mouse model [52].